U.K. cabinet shuffle, Taiwan biotech and Biogen data — a BioCentury podcast

Plus: Lilly’s psychedelic play and what’s new at FDA

The departure of U.K. Science Minister Patrick Vallance is a blow for U.K. biotech. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss what Vallance’s exit, the appointment of John Healey as Chancellor of the Exchequer, and other changes arriving with the new Prime Minister could mean for life sciences in the country.

BioCentury’s analysts also discuss an ambitious U.K. data initiative launched this month. The Health Data Research Service is intended to be a single front door to all NHS health records, offering large-scale longitudinal health data across diverse populations.

Beyond the U.K., the team turns to companies to watch in Taiwan, what’s next for Biogen Inc.’s anti-tau therapy diranersen after the company’s latest Phase II data, Eli Lilly and Co.’s proposed acquisition of psychedelics company AtaiBeckley Inc., and the latest changes at FDA.